| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 27,734 | 33,374 | ||
| Research and development tax credit receivable | 1,704 | 1,605 | ||
| Other tax receivable | 760 | 550 | ||
| Prepaid expenses and other current assets | 472 | 505 | ||
| Total current assets | 30,670 | 36,034 | ||
| Equipment, net | 878 | 706 | ||
| Operating lease right of use asset | 1,064 | 374 | ||
| Acquired in-process research and development intangible assets | - | 0 | ||
| Other assets | 746 | 570 | ||
| Total assets | 33,358 | 37,684 | ||
| Accounts payable and accrued liabilities | 6,875 | 7,671 | ||
| Deferred liabilities | - | 511 | ||
| Accounts payable and accrued liabilities related parties-Related Party | 25 | 184 | ||
| Operating lease, current liabilities | 457 | 220 | ||
| Total current liabilities | 7,357 | 8,586 | ||
| Long-term operating lease liabilities | 623 | 231 | ||
| Total liabilities | 7,980 | 8,817 | ||
| Common stock, 0.001 par value, 200,000,000 shares authorized, 26,585,258 and 22,280,451 shares issued and outstanding, respectively | 27 | 27 | ||
| Additional paid-in capital | 229,888 | 226,904 | ||
| Accumulated other comprehensive loss | -764 | -763 | ||
| Accumulated deficit | -203,773 | -197,301 | ||
| Total stockholders equity | 25,378 | 28,867 | ||
| Total liabilities and stockholders equity | 33,358 | 37,684 | ||
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)